Travis, Ruth CPerez-Cornago, AuroraAppleby, Paul NAlbanes, DemetriusJoshu, Corinne ELutsey, Pamela LMondul, Alison MPlatz, Elizabeth AWeinstein, Stephanie JLayne, Tracy MHelzlsouer, Kathy JVisvanathan, KalaPalli, DomenicoPeeters, Petra HBueno-de-Mesquita, BasTrichopoulou, AntoniaGunter, Marc JTsilidis, Konstantinos KSánchez, Maria-JoseOlsen, AnjaBrenner, HermannSchöttker, BenPerna, LauraHolleczek, BerndKnekt, PaulRissanen, HarriYeap, Bu BFlicker, LeonAlmeida, Osvaldo PWong, Yuen Yee ElizabethChan, June MGiovannucci, Edward LStampfer, Meir JUrsin, GiskeGislefoss, Randi EBjørge, ToneMeyer, Haakon EBlomhoff, RuneTsugane, ShoichiroSawada, NorieEnglish, Dallas REyles, Darryl WHeath, Alicia KWilliamson, Elizabeth JManjer, JonasMalm, JohanAlmquist, MartinMarchand, Loic LeHaiman, Christopher AWilkens, Lynne RSchenk, Jeannette MTangen, Cathy MBlack, AmandaCook, Michael BHuang, Wen-YiZiegler, Regina GMartin, Richard MHamdy, Freddie CDonovan, Jenny LNeal, David ETouvier, MathildeHercberg, SergeGalan, PilarDeschasaux, MélanieKey, Timothy JAllen, Naomi E2023-01-252023-01-252018-11-13http://hdl.handle.net/10668/13183Previous prospective studies assessing the relationship between circulating concentrations of vitamin D and prostate cancer risk have shown inconclusive results, particularly for risk of aggressive disease. In this study, we examine the association between prediagnostic concentrations of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D] and the risk of prostate cancer overall and by tumor characteristics. Principal investigators of 19 prospective studies provided individual participant data on circulating 25(OH)D and 1,25(OH)2D for up to 13,462 men with incident prostate cancer and 20,261 control participants. ORs for prostate cancer by study-specific fifths of season-standardized vitamin D concentration were estimated using multivariable-adjusted conditional logistic regression. 25(OH)D concentration was positively associated with risk for total prostate cancer (multivariable-adjusted OR comparing highest vs. lowest study-specific fifth was 1.22; 95% confidence interval, 1.13-1.31; P trendenAgedCase-Control StudiesCross-Sectional StudiesHumansMaleMiddle AgedOdds RatioProspective StudiesProstatic NeoplasmsRisk AssessmentRisk FactorsVitamin Dresearch article30425058open access10.1158/0008-5472.CAN-18-23181538-7445PMC6330070https://europepmc.org/articles/pmc6330070?pdf=renderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330070/pdf